BACKGROUND A major cause of morbidity and functional disability in acromegaly is
represented by axial and peripheral arthropathy. OBJECTIVE The effect of a 12‐month …

Radiation Oncology: An Evidence-Based Approach (ROEBA) is a reference book designed
to enable radiation oncologists, including those in training, to make diagnostic and treatment …

We report our preliminary results concerning 25 patients with secreting pituitary adenomas
treated with stereotactic radiosurgery after partial transsphenoidal surgery and followed over …

Objective Acromegaly is a disease characterized by GH hypersecretion, and is typically
caused by a pituitary somatotroph adenoma. The primary mode of therapy is surgery, and …

Medical therapy has taken on a more important role in the management of patients with
acromegaly as the limitations of pituitary surgery and radiation have become apparent …

Dopamine agonists have been used as adjunctive therapy for acromegaly for many years,
but relatively few studies have assessed the efficacy of a newer agonist, cabergoline. Some …

This chapter contains sections titled: Endocrine disorders; Cutaneous markers of internal
malignancy [1-11]; The gastrointestinal tract; Liver disease; Pancreatic disease; Renal …

Summary objective Somatostatin is an endogenous inhibitor of hormone secretion and cell
proliferation. Treatment with somatostatin analogues in humans causes a reduction in size …

Objective: Nearly 40% of acromegalic patients fail to control GH/IGF-I levels with
somatostatin analogues (SA). Dopaminergic agonists (DA) are even less effective, but …

Prolactin (PRL) and growth hormone (GH) act by way of their receptors as either hormones
(systemically) or cytokines (locally). The Jak2/Stat5 pathway is the principal route by which …